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Abstract
Background: Using antibody/aptamer-drug conjugates can be a promising method for decreasing toxicity, while increasing
the efficiency of chemotherapy.
Methodology/Principal Findings: In this study, the antitumor agent Doxorubicin (Dox) was incorporated into the modified
DNA aptamer TLS11a-GC, which specifically targets LH86, a human hepatocellular carcinoma cell line. Cell viability tests
demonstrated that the TLS11a-GC-Dox conjugates exhibited both potency and target specificity. Importantly, intercalating
Dox into the modified aptamer inhibited nonspecific uptake of membrane-permeable Dox to the non-target cell line. Since
the conjugates are selective for cells that express higher amounts of target proteins, both criteria noted above are met,
making TLS11a-GC-Dox conjugates potential candidates for targeted delivery to liver cancer cells.
Conclusions/Significance: Considering the large number of available aptamers that have specific targets for a wide variety
of cancer cells, this novel aptamer-drug intercalation method will have promising implications for chemotherapeutics in
general.
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Introduction
It is well known that traditional cancer chemotherapy agents
can cause serious side effects by their nonspecific toxicity. To
overcome this problem and achieve specific drug delivery, our
group and other investigators have used antibodies [1,2] or
aptamers [3,4,5,6,7,8,9,10] to design ligand-linked drug conju-
gates for targeted-delivery applications.
Aptamers are single-stranded oligonucleotides which can
specifically bind to small molecules, [11] peptides and proteins.
[12] Aptamers not only provide the advantages of antibodies, such
as high specificity and affinity, but they also have low
immunogenicity and high stability, with easy synthesis and
modification. Recently, a process called cell-SELEX (Systematic
Evolution of Ligands by Exponential enrichment) has been
developed to generate aptamers for specific recognition of target
cancer cells, including T-cell acute lymphoblastic leukemia (T-cell
ALL), small-cell lung cancers, liver cancers and virus-infected cells.
[13,14,15,16,17,18,19] These aptamers are highly specific for
different types of tumor cells and have excellent binding affinities.
Because aptamers provide specificity at the molecular level, it is
believed that aptamer-drug conjugates may enhance the efficiency
of drug delivery, while at the same time, decreasing systemic
toxicity.
Hepatocellular carcinoma (HCC) is one of the most common
and deadly cancers in the world. It causes approximately 600,000
deaths every year. Currently, treatments for early liver cancer have
relied on liver transplantation and surgical resection. Conventional
chemotherapy has not been efficient with liver cancer patients,
and since the chemotherapeutic agents are not specific to liver
cancer cells, toxic side effects result. In a previous publication, we
reported the development of a series of specific aptamers based on
a mouse model. [14] One of these aptamers can also specifically
recognize human liver cancer cells, and we report here a new
design for the targeted delivery of Doxorubicin (Dox) to liver
cancer cells.
Doxorubicin has been used for the treatment of liver cancer in
the form of localized delivery, but its efficacy is impeded by toxic
side effects. To overcome this problem, we have intercalated Dox
into a modified aptamer probe. Dox is known to intercalate into
the DNA strand by the presence of flat aromatic rings in the Dox
molecule. Recent research has already shown that Doxorubicin
can intercalate into aptamer A10 to provide specific killing
efficiency to prostate cancer cells. [6,20].
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e33434Aptamer TLS11a was previously selected by cell-SELEX
against the BNL 1ME A.7R.1 (MEAR) mouse hepatoma cell
line. [14] It was chosen for this application because it showed great
binding affinity for LH86, a liver cancer cell line. [21] In order to
achieve greater intercalation efficiency, a long GC tail was added
to TLS11a to form a modified aptamer, TLS11a-GC. Through
the interaction, the ratio between Doxorubicin and TLS11a-GC
was 25:1. Consequently, the delivery efficiency of Doxorubicin was
much higher compared to the original TLS11a. Also, in vitro and in
vivo experiments showed that TLS11a-GC-Dox conjugates have
much better specific killing efficiency for target cancer cells
compared to free Dox and control aptamer-Dox conjugates.
Results
The Binding Affinity of Aptamer TLS11a
Aptamer TLS11a (Fig. 1a) was generated against the BNL 1ME
A.7R.1 (MEAR) mouse hepatoma cell line [14] and showed strong
binding affinity (Kd=4.5160.39 nM). [14] The LH86 cell line
was established from a patient with liver cancer. [21] When
TLS11a was used to test LH86 cells, obvious binding ability was
observed (Fig. 1b). Also, when human normal liver cells, Hu1082,
were tested using TLS11a, no significant binding was observed
(Fig. 1c). In Fig. 1b and c, the green histogram shows the
background binding (control aptamer, TD05), and the red
fluorescence intensities show the binding of TLS11a with target
and control cells. Compared to the control aptamer, there is
a significant difference between the binding strength of TLS11a to
LH86 and Hu1082 cells. No previously reported probe differ-
entiates between liver cancer cells and human normal liver cells.
Also, the Kd of TLS11a to LH86 was 7.1660.59 nM (Fig. 1d),
compared to 4.5160.39 nM to BNL 1ME A.7R.1. [14].
Immunohistological imaging and fluorescence microscopy have
been widely used in the study of solid tumors; therefore, we also
assessed whether TLS11a could be used for tumor imaging with
LH86, the positive cell line. Figure S1 shows the confocal images
of LH86 detected with TLS11a and a control sequence, TD05
(Text S1). There was significant signal strength of TLS11a
compared with the negative control, and the signal pattern shows
that the aptamers bind to the surface of the cells.
It is usually assumed that aptamers selected against cell lines
bind to cell membrane proteins. This has been demonstrated in
most SELEX protocols involving tumor cell lines. [22,23] In order
to investigate the target molecule of TLS11a, we performed
a protease assay, in which LH86 cells were treated with trypsin for
10 min at 37uC. After the incubation period, the protease activity
was stopped with the addition of ice-cold PBS containing 20%
FBS. The cells were quickly washed twice by centrifugation and
then incubated with the aptamers. As shown in Figure S2, TLS11a
lost recognition significantly in trypsin-treated cells (Text S1). The
fluorescence signals reduced to the background, indicating that the
treatment of the cells with the proteases caused digestion of the
target protein, in turn showing that the target molecule of TLS11a
is a membrane protein.
An internalization assay was then performed to determine if
TLS11a could be internalized upon target binding. LH86 cells
were first incubated with biotin- labeled TLS11a or TD05 and
then further incubated with streptavidin- conjugated PE-Cy5.5.
Then the buffer was removed, and culture medium with
LysoSensor
TM Green DND-189 was added to the cells and
incubated at 37uC for two hours. LysoSensor served as an
indicator of the lysosome location in the cells. As shown in Figure
S3, there was clear internalization of the aptamer (Text S1). The
TLS11a signal originated from inside the cells rather than on the
outer margins, and it co-localized with LysoSensor. The control
Figure 1. Characterization of aptamer TLS11a. (a) The secondary structure of aptamer TLS11a and its binding ability to (b) LH86 and (c) human
normal liver cells, Hu1082. The green histogram shows the background binding (control aptamer, TD05), and the red fluorescence intensities show
the binding of TLS11a with target and control cells. All probes were labeled with Phycoerythrin-Cy5.5. (d) Kd determination.
doi:10.1371/journal.pone.0033434.g001
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results suggest that TLS11a may have bound to a protein that
could be internalized.
Conjugation and Property Study of Aptamer-Dox
Complex
Dox is known to intercalate within the DNA strand by the
presence of flat aromatic rings, and it preferentially binds to
double-stranded 59-GC-39 or 59-CG-39 sequences. [24,25]. The
secondary structure of TLS11a, as predicted by NUPACK
software (http://www.nupack.org/), is shown in Figure 1a.
According to the structure, there are two 59-GC-39 or 59-CG-39
sequences in the TLS11a sequence such that one TLS11a
sequence can intercalate a maximum of two Doxorubicin
molecules. In order to intercalate more Doxorubicin molecules,
a long GC tail was added to the 59 end of TLS11a to generate
a modified aptamer, TLS11a-GC (Fig. 2a). Because of the long
GC tail, TLS11a-GC forms a dimer structure. Nupack calculation
indicated that one TLS11a-GC dimer could intercalate up to 56
Doxorubicin molecules to produce a TLS11a-GC-to-Doxorubicin
ratio of 1:28. A control aptamer sequence, TD05, was also
modified with a long GC tail to give the same aptamer to
Doxorubicin ratio (Fig. 2b). Even though the TLS1a-GC and
TD05-GC dimers could intercalate up to 28 Dox per aptamer, the
ratio between aptamer and Doxorubicin was kept at 1:25 in these
experiments.
It is well known that Dox has fluorescence properties, but the
intercalation of Dox into DNA aptamer quenches the
fluorescence of Dox because of the formation of charge-transfer
complexes between the DNA bases and the anthracycline ring.
[26,27,28] To examine whether such interaction occurs with
modified TLS11a-GC and TD05-GC aptamers, fluorescence
was acquired for Dox in the absence and in the presence of one
of the aptamers (Fig. 2c). The solution of free Dox had the
highest fluorescence signal compared to the black group
(binding buffer). When modified aptamer (TLS11a-GC or
TD05-GC) was added to the Dox solution at 1:28 ratio and
mixed well, the fluorescence dramatically decreased almost to
the background level, indicating that the intercalation of Dox
into DNA aptamer is feasible and rapid. Even after the
aptamer-Dox complex solution was kept at room temperature
for 3 h, the fluorescence stayed the same, indicating that the
aptamer-Dox complex is very stable.
The binding affinity of TLS11a-GC was determined by
a competition method. After incubating with unlabeled TLS11a-
GC, the binding sites on LH86 cells were completely occupied.
Then all cells were further incubated with dye-labeled TLS11a.
Because all binding sites on the cell membrane were occupied
by unlabeled TLS11a-GC, dye-labeled TLS11a could not bind
to LH86 cells, and after washing no fluorescence signal was
detected (Fig. 2d). At the same time, a competition experiment
between TD05-GC and dye- labeled TLS11a was carried out.
Because TD05-GC did not bind to LH86, the binding sites
were available for interaction with dye-labeled TLS11a,
resulting in a high fluorescence signal (Fig. 2e). After
modification with the long GC tail, the flow cytometry data
clearly showed that TLS11a-GC could still bind to LH86 cells,
while TD05-GC could not.
Doxorubicin release was investigated using confocal microsco-
py. After 1 h incubation with Doxorubicin or aptamer-Dox
Figure 2. The secondary structure of aptamer-Dox conjugates and their recognition of target cells. The intercalation of Dox into GC-
modified aptamers formed physical conjugates. (a) TLS11a-GC-Dox. (b) TD05-GC-Dox. (c) Quenching of Dox fluorescence after intercalation. The
binding affinity of (d) TLS11a-GC or (e) TD05-GC to LH86 cells monitored using flow cytometry. The fluorescence signal is from Phycoerythrin-Cy5.5.
Internalization of (f) Dox, (g) TLS11a-gc-Dox, and (h) TD05-GC-Dox observed by confocal microscopy.
doi:10.1371/journal.pone.0033434.g002
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imaging. Figure 2f shows that cells treated with free Doxorubicin
had the most Doxorubicin in their nuclei, while the nuclei of cells
treated with TLS11a-GC-Dox conjugates (Fig. 2g) also contained
Doxorubicin. However, the nuclei of cells treated with TD05-GC-
Dox conjugates (Fig. 2h) contained almost no Doxorubicin. This
experiment confirmed that TLS11a-GC-Dox conjugates had
specific binding affinity to LH86 cells compared to TD05-GC-
Dox conjugates. Furthermore, Dox could be released from
TLS11a-GC-Dox conjugates after internalization and could enter
the nucleus.
Cell Toxicity of Aptamer-Dox Conjugates
The cell viability of LH86 treated with TLS11a-GC-Dox,
TD05-GC-Dox, Doxorubicin, TLS11a-GC, or TD05-GC was
tested and compared to that of untreated cells (Fig. 3a). The
Doxorubicin concentration in TLS11a-GC-Dox, TD05-GC-Dox,
and free Doxorubicin was kept at 7.5 mM, and the ratio of
Doxorubicin to aptamer was 25:1. The aptamer concentration in
the TLS11a-GC, TD05-GC, TLS11a-GC-Dox, and TD05-GC-
Dox groups was kept at 300 nM. From the data shown in
Figure 3a, TLS11a-GC and TD05-GC had no significant effect on
cell viability. It is obvious that treatment with TLS11a-GC-Dox
conjugates decreased cell viability. The efficiency of cell toxicity
was Doxorubicin .TLS11a-GC-Dox.TD05-GC-Dox. Even
though the cell toxicity of TLS11a-GC-Dox was less than that of
free Doxorubicin, the toxicity effect of TD05-GC-Dox was much
poorer. Further experiments using Hu1229 human normal liver
cells (Fig. 3b) showed that free Dox had significant toxicity, while
TLS11a-GC-Dox and TD05-GC-Dox had similar and very
limited toxicity. These data demonstrate that the specificity of
aptamer TLS11a-GC to LH86 cells achieved toxicity to target
cells only.
Cell apoptosis was investigated using Hoechst 33258 staining
(Fig. 3c). From the fluorescence images, when the Dox
concentration was 60 mM, there were more apoptotic and dead
cells in the TLS11a-GC-Dox group (35.1%) than in the TD05-
GC-Dox group (13.7%), further indicating the specificity of
aptamer-Dox conjugates. In addition, caspase 3 activation was
monitored using Western blot (Fig. 3d). Caspase 3 plays an
important role in cell apoptosis, and cleaved caspase 3 indicates its
activation. From the data shown, when the Dox concentration was
60 mM, the band density of cleaved caspase 3 in cells treated with
TLS11a-GC-Dox was 3.3 times higher than that in cells treated
with TD05-GC-Dox.
In Vivo Studies
Thirty NOD. Cg-Prikdc (scid) IL2 mice were treated as
described in the experimental section. The tumor size of each
mouse was measured every other day, and the average tumor
volume was calculated (Fig. 4a). The data show that both free
Dox and TLS11a-GC-DOX complex had obvious tumor
inhibition effects compared to the untreated group. Also, the
TLS11a-GC-DOX complex had a more efficient effect
compared to free Dox, indicating that TLS11a-GC-Dox
conjugates targeted the tumor cells and achieved higher local
Dox concentration in the tumor site compared to free Dox.
Also, tumors of each mouse were collected and fixed using 10%
formalin for 24 h. Then all samples were sent to the molecular
pathology core lab for H&E staining. From the H&E stained
slides, the TLS11a-GC-DOX complex-treated tumor (Fig. 4b,
right) showed significant tumor cell necrosis compared to the
untreated tumor (Fig. 4b, left).
Discussion
Aptamer TLS11a was generated using mouse liver cancer cells,
but it also shows high binding affinity to human liver cancer cells.
Furthermore, TLS11a is the first aptamer to be identified as
specific for human liver cancer cells. Our results showed that the
target molecule of TLS11a is very likely a membrane protein
which can be internalized into cells. These results indicate that
TLS11a may be a useful aptamer for targeted drug delivery in
liver cancer treatment.
Doxorubicin plays a very important role in liver cancer
treatment, and it is considered to be the most utilized anticancer
drug worldwide. Dox is able to inhibit cell proliferation through
intercalation of DNA in the cell’s nucleus. Several reports have
demonstrated that free Dox is membrane-permeable and can be
uptaken by cells through a passive diffusion mechanism, rapidly
transported to the nuclei, and bound to the chromosomal DNA.
[29] Therefore, while Dox is generally toxic to proliferating cells, it
is also toxic to normal cells, thus limiting its therapeutic efficacy in
clinical use. Here, by making use of modification of a specific liver
cancer aptamer and the intercalation property of Dox, we
generated an easy, rapid, and efficient method to deliver Dox to
targeted cancer cells. During in vitro experiments, we proved the
specific binding affinity of modified TLS11a-GC to target LH86
cells, but non-recognition to human normal liver cells. Further-
more, we demonstrated the specific toxicity of TLS11a-GC-Dox
complex to target cells, compared to normal liver cells, thereby
limiting its toxicity to only target cells. This targeting was achieved
through the specific binding affinity of aptamer TLS11a. Although
TLS11a-GC-Dox achieved good cell toxicity compared to control
TD05-GC-Dox during MTS assay, less toxicity was observed in
the TLS11a-GC-Dox group than in the free Dox group. Also, less
internalization and release of Dox in the TLS11a-GC-Dox group
than in the free Dox group was observed using confocal
microscopy. Dox itself is a small molecule which can be rapidly
uptaken by cells through a passive diffusion mechanism. Within
15 min, cells treated with free Dox show an intense red
fluorescence in the nuclear region, indicating that the uptake
speed is very rapid. [29] However, once Dox was intercalated into
DNA aptamer to form a much larger molecule, the cell uptake of
aptamer-Dox complex was mainly dependent on the aptamer and
its cell membrane target. In addition, aptamer internalization
required more time (about 2 h) than free Dox, thus slowing the
internalization of aptamer-Dox complex and the release of Dox
from the complex. Therefore, less toxicity was observed in the
TLS11a-GC-Dox group than in the free Dox group during in vitro
experiments. During in vivo experiments, TLS11a-GC-Dox had
decreased cell internalization speed compared to free Dox.
However, because of target recognition by TLS11a aptamer, the
local concentration of Dox was increased, compared to free Dox.
Hence, higher tumor inhibition efficacy was achieved in the
TLS11a-GC-Dox-treated mouse group.
In summary, by making use of the ability of anthracycline drugs
to intercalate between bases of nucleotides, a new design to modify
aptamer TLS11a to TLS11a-GC and make Dox and TLS11a-GC
conjugates was investigated. The specificity and efficacy of this
conjugate to serve as a drug-delivery platform was further
demonstrated in vitro and in vivo. Our data showed that the
modified aptamer retains its specificity and can load much more
Dox than the unmodified aptamer. Also, the aptamer-Dox
conjugates are stable in cell culture medium and can differentially
target LH86 cells. The specificity of this system was further
demonstrated by treatment of human normal liver cells, which
lack the aptamer binding target. The aptamer-Dox conjugate
Targeted Liver Chemotherapy
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toxicity to the non-target cells. Furthermore, the in vivo experiment
showed better tumor inhibition by the TLS11a-GC-Dox group
compared to all other control groups, indicating the successful
delivery of Dox by the modified aptamer. This targeting specificity
assured a higher local Dox concentration in the tumor. In
addition, aptamer-Dox conjugates are smaller than antibody-
based drug delivery systemsand some other delivery system,
[30,31] allowing faster penetration and fewer immunoreactions.
We anticipate that the newly designed aptamer-Dox conjugation
platform, which is based on the intercalation of anthracyclines
within the bases of aptamers, may be utilized in distinct ways to
develop novel targeted therapeutic modalities for more effective
cancer chemotherapy.
Materials and Methods
Cell Culture and Reagents
LH86 cells have been described previously. [21] Cells were
cultured in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) (heat
inactivated) and 100 IU/mL penicillin-streptomycin at 37uCi n
a humid atmosphere with 5% CO2. Doxorubicin hydrochloride
(Dox) was purchased from Fisher Scientific (Houston, TX,
USA). All reagents for DNA synthesis were purchased from
Glen Research. Unless otherwise noted, reactants, buffers and
solvents were obtained commercially from Fisher Scientific.
Figure 3. Relative cell viability and apoptosis of cells treated with TLS11a-GC, TD05-GC, free Doxorubicin, TLS11a-GC-Dox or TD05-
GC-Dox. (a) Relative cell viability of LH86 (target cell line); (b) Relative cell viability of Hu1229 (human normal liver cells); (c) Hoechst 33258 staining
for apoptotic and dead LH86 cells treated with a series of concentrations of TLS11a-GC-Dox or TD05-GC-Dox; (d) Western blot results for cleaved
caspase 3 in LH86 cells treated with a series of concentrations of TLS11a-GC-Dox or TD05-GC-Dox.
doi:10.1371/journal.pone.0033434.g003
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Aptamer TLS11a (59- ACAGCATCCCCATGTGAACAATCG-
CATTGTGATTG TTACGGTTTCCGCCTCATGGACGTGCTG -
39); a control sequence TD05.
(59-CACCGGGAGGATAGTTCGGTGGCTGTT-




TACGGTTTCCGCCTCATGGACGTGCT G -39); and modified




synthesized on an ABI3400 DNA/RNA synthesizer (Applied
Biosystems, Foster City, CA, USA). The completed sequences
were then deprotected in AMA (ammonium hydroxide/40%
aqueous methylamine 1:1) at 65uC for 30 min and further purified
by reversed-phase HPLC (ProStar, Varian, Walnut Creek, CA,
USA) on a C-18 column using 100 mM trimethylamine acetate
buffer (TEAA, pH7.5) and acetonitrile as the mobile phase. To
make aptamer-Dox conjugates, either TLS11a-GC or TD05-GC
was mixed with Doxorubicin in binding buffer (PBS containing
5 mM MgCl2, 4.5 mg/mL glucose, 0.1 mg/mL yeast tRNA,
1 mg/mL BSA) or DMEM media at a 1:25 ratio of aptamer to
Dox.
Monitoring of Complex Formation by Fluorescence
Physical conjugates between aptamer (TLS11a or TD05) and
Doxorubicin were prepared at a 1:28 molar ratio of aptamer to
Doxorubicin (10 mM) in binding buffer, and fluorescence was
monitored at 500–720 nm (1.5 mm slit) on a Fluorolog-Tau-3
Spectrofluorometer (Jobin Yvon) with excitation at 480 nm.
Determination of Aptamer Affinity
The LH86 cells were detached from dishes using nonenzymatic
cell dissociation solution (Cellgro) and then washed with washing
buffer (PBS containing 5 mM MgCl2 and 4.5 mg/mL glucose).
The binding affinity of TLS11a was determined by incubating
LH86 cells (10
5) on ice for 30 min with a series of concentrations
of biotin-labeled TLS11a in binding buffer (100 mL). Cells were
then washed twice with washing buffer (1.0 mL) and suspended in
fluorescein-labeled streptavidin (0.1 mL) for further incubation
(15 min on ice). Before flow cytometric analysis, cells were washed
with washing buffer twice and suspended in washing buffer
(0.2 mL). The mean fluorescence intensity of cells was used to
calculate the equilibrium dissociation constant (Kd) of the TLS11a
and LH86 cell interaction by fitting the dependence of
fluorescence intensity (F) on the concentration of the biotin-
labeled TLS11a (L) to the equation F=Bmax[L]/(Kd+[L]). The
binding assay experiments were repeated at least three times.
To monitor the binding affinity of TLS11-GC, a competition
experiment was carried out. Briefly, 200 nM TLS11a-GC was
Figure 4. Tumor inhibition of the aptamer-Dox complex in mouse model. (a) Average tumor volume of mice treated with nothing (black),
Doxorubicin (red), or TLS11a-GC-Dox (blue); (b) Microscopy images of H&E stained tumor tissue slides.
doi:10.1371/journal.pone.0033434.g004
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biotin-labeled TLS11a was added for 15 min further incubation.
Cells were then washed twice with washing buffer (1.0 mL) and
suspended in fluorescein-labeled streptavidin (0.1 mL) for further
incubation (15 min on ice). Before flow cytometric analysis, cells
were washed with washing buffer twice and suspended in washing
buffer (0.2 mL).
Assessment of Cell Uptake of Dox by Confocal
Microscopy
For confocal imaging, Doxorubicin or aptamer-Dox conjugates
were incubated with a LH86 cell monolayer in a 35-mm glass
bottom culture dish (Mat Tek Corp.) in DMEM media at 37uC for
1 h. After washing once using media, fresh media were added to
dishes for further 3 h incubation at 37uC. Then the dishes with
cells were placed above a 406objective of an Olympus FV500-
IX81 confocal microscope (Olympus America Inc., Melville, NY).
A 5-mW, 488-nm Ar+ laser was then used for excitation of
Doxorubicin. The objective used for imaging was an Olympus LC
Plan F1 40X/0.60 ph 2 406objective.
MTS Cell Viability Assay
Chemosensitivity of LH86 to Dox or aptamer-Dox conjugates
was determined using the CellTiter 96 cell proliferation assay
(Promega, Madison, WI, USA). Briefly, a 100 mL aliquot of LH86
cells (5610
4 cells/mL) was seeded in 96-well plates (n=3) and
allowed to grow overnight. Afterwards, cells were treated with
100 mL of: 1) control aptamer TD05-GC, 2) aptamer TLS11a-
GC, 3) Dox, 4) TD05-GC-Dox physical conjugate (25:1
Doxorubicin to TD05-GC mole ratio), or 5) TLS11a-GC-Dox
physical conjugate (25:1 Doxorubicin to TLS11a mole ratio) for 1
hour, washed, and further incubated in fresh media for a total of
48 hrs. For cytotoxicity measurement, media were removed from
each well, and then CellTiter reagent (20 mL) and media (100 mL)
were added to each well and incubated for 3 h. Using a plate
reader (Tecan Safire microplate reader, AG, Switzerland), the
absorption was recorded at 490 nm. The percentage of cell
viability was determined by comparing Dox and aptamer-Dox
conjugate-treated cells with the untreated control.
Hoechst 33258 Staining for Apoptotic Cells
Cell apoptosis was determined by nucleus morphology change.
LH86 cells in exponential growth were placed in a 48-well plate at
a final concentration of 1.5610
4 cells per well. After 12 h, cells
were treated with different concentrations of TD05-GC-Dox
physical conjugate (25:1 Doxorubicin to TD05-GC mole ratio) or
TLS11a-GC-Dox physical conjugate (25:1 Doxorubicin to
TLS11a mole ratio) for 1 hour, washed, and further incubated
in fresh media for a total of 48 hrs. Subsequently, cells were
washed twice with PBS and stained with Hoechst 33258 staining
solution according to the manufacturer’s instructions. After
incubation at 37uC for 10 min, cell nucleus fragmentation/
condensation was detected by fluorescence microscopy. Apoptotic
cell death was assessed by calculating the number of apoptotic cells
with condensed nuclei in six to eight randomly selected areas. The
results shown represent three independent experiments.
Western Blotting Analysis
Cells were harvested and washed twice with phosphate saline
buffer. The cell pellets were resuspended in lysis buffer containing
Nonidet P-40 (10 mM HEPES, pH 7.4, 2 mM EGTA, 0.5%
Nonidet P-40, 1 mM NaF, 1 mM NaVO4, 1 mM phenylmethyl-
sulfonyl fluoride, 1 mM dithiothreitol, 50 mg/ml trypsin inhibitor,
10 mg/ml aprotinin, and leupeptin) and incubated on ice for
30 min. After centrifugation at 120006ga t4 uC for 15 min, the
supernatant was transferred to a fresh tube, and the protein
concentration was determined. Equivalent samples (20 mgo f
protein) were subjected to SDS-PAGE on 12% gels. The proteins
were transferred onto nitrocellulose membranes and probed with
the indicated primary antibodies (cleaved caspase-3 antibody, Cell
Signaling Technology, Inc.), followed by the appropriate second-
ary antibodies conjugated with horseradish peroxidase (HRP,
Santa Cruz Biotechnology, Inc.). Immunoreactive bands were
detected using enhanced chemiluminescence (ECL, Pierce). The
molecular sizes of the proteins detected were determined by
comparison with prestained protein markers (Bio-Rad). All band
densities were calculated using ImageJ software.
In vivo Experiment
The NOD. Cg-Prkdc (scid) IL2 mice were purchased from
Jackson Laboratory (Bar Harbor, ME) and housed in the animal
facility at the University of Florida with institutional regulatory
approval (Institutional Animal Care and Use Committee). This
study was approved by Institutional Animal Care and Use
Committee with approval ID IC00001331. Thirty NOD. Cg-
Prkdc (scid) IL2 mice were subcutaneously injected with 7610
6 in
vitro-propagated LH86 cells. When the tumors could be easily seen
and measured, mice were divided into three groups: (1) group 1,
untreated; (2) group 2, treated with free Dox; and (3) group 3,
treated with TLS11a-GC-DOX complex. The Doxorubicin
dosage was kept the same in groups 2 and 3 at 2 mg/kg. All
treatments continued for 11 days. Drugs were injected through tail
vein on days 1, 2, 3, 4, 5, 9, 10, and all samples were collected on
day 11. The tumor size for each mouse was measured every other
day. The heart, lung, liver, kidney and tumor of each mouse were
collected on day 11 and fixed using 10% formalin for 24 h at room
temperature, and then hematoxylin and eosin staining (H&E
staining) was carried out.
Supporting Information
Figure S1 Confocal images of aptamer staining with
cultured LH86 cells. Cells were incubated with aptamer
conjugated with biotin, and the binding event was observed with
AlexaFluor 633-conjugated streptavidin. Non-binding sequence
TD05 showed the background binding. Aptamers show significant
binding over the background signal.
(TIF)
Figure S2 Preliminary determination of the type of cell-
surface molecule which binds to TLS11a. Cells were treated
with trypsin for 10 min and then incubated with aptamer.
(TIF)
Figure S3 Co-localization of (a) TLS11a or (b) control
TD05 and Lysosensor in endosomes after two hours of
incubation at 37uC.
(TIF)
Text S1 Supporting methods.
(DOC)
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